933 related articles for article (PubMed ID: 32077218)
21. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
[TBL] [Abstract][Full Text] [Related]
22. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Powell JR; Wittwer JA; Chu JX; Sewell KA; Wu Q; Cummings DM
Diabetes Obes Metab; 2019 Oct; 21(10):2274-2283. PubMed ID: 31168889
[TBL] [Abstract][Full Text] [Related]
23. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Okunrintemi V; Jain S; Sewell KA; Powell JR; Cummings DM
Diabetes Metab; 2021 Feb; 47(1):101160. PubMed ID: 32439471
[TBL] [Abstract][Full Text] [Related]
24. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
de Wit HM; Te Groen M; Rovers MM; Tack CJ
Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E
Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kobayashi K; Toyoda M; Hatori N; Sakai H; Furuki T; Sato K; Terauchi Y; Tamura K; Kanamori A
Sci Rep; 2022 Sep; 12(1):16106. PubMed ID: 36167964
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
[TBL] [Abstract][Full Text] [Related]
31. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
Sohn M; Dietrich JW; Nauck MA; Lim S
Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
[TBL] [Abstract][Full Text] [Related]
32. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence.
Sammour Y; Nassif M; Magwire M; Thomas M; Fendler T; Khumri T; Sperry BW; O'Keefe J; Kosiborod M
J Heart Lung Transplant; 2021 Jun; 40(6):426-429. PubMed ID: 33745782
[TBL] [Abstract][Full Text] [Related]
33. Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States.
Nargesi AA; Clark C; Aminorroaya A; Chen L; Liu M; Reddy A; Amodeo S; Oikonomou EK; Suchard MA; McGuire DK; Lin Z; Inzucchi S; Khera R
Am J Cardiol; 2023 Jun; 196():89-98. PubMed ID: 37012183
[TBL] [Abstract][Full Text] [Related]
34. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
[TBL] [Abstract][Full Text] [Related]
35. An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is).
Wen S; Nguyen T; Gong M; Yuan X; Wang C; Jin J; Zhou L
Diabetes Metab Syndr Obes; 2021; 14():2955-2972. PubMed ID: 34234493
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes.
Mishriky BM; Cummings DM; Powell JR
Prim Care Diabetes; 2022 Jun; 16(3):471-473. PubMed ID: 35396200
[TBL] [Abstract][Full Text] [Related]
37. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.
Yang S; He W; Zhao L; Mi Y
PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174
[TBL] [Abstract][Full Text] [Related]
38. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q; Nong K; Vandvik PO; Guyatt GH; Schnell O; Rydén L; Marx N; Brosius FC; Mustafa RA; Agarwal A; Zou X; Mao Y; Asadollahifar A; Chowdhury SR; Zhai C; Gupta S; Gao Y; Lima JP; Numata K; Qiao Z; Fan Q; Yang Q; Jin Y; Ge L; Yang Q; Zhu H; Yang F; Chen Z; Lu X; He S; Chen X; Lyu X; An X; Chen Y; Hao Q; Standl E; Siemieniuk R; Agoritsas T; Tian H; Li S
BMJ; 2023 Apr; 381():e074068. PubMed ID: 37024129
[TBL] [Abstract][Full Text] [Related]
39. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
[TBL] [Abstract][Full Text] [Related]
40. Translating trial results into interpretable risk estimates: Systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.
Rizzi A; Kloecker DE; Pitocco D; Khunti K; Davies MJ; Zaccardi F
Nutr Metab Cardiovasc Dis; 2024 May; 34(5):1129-1133. PubMed ID: 38336546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]